Lyell Immunopharma, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $4.0K | — | $2.0K | — | — | — | $15.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $39.5M | — | $36.6M | — | — | — | $28.2M |
| SG&A Expense | — | $9.6M | — | $9.6M | — | — | — | $10.7M |
| Operating Income | — | $-47.3M | — | $-44.3M | — | — | — | $-37.3M |
| Operating Margin | — | -1,183,425.0% | — | -2,213,050.0% | — | — | — | -248,353.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-44.8M | — | $-24.2M | — | — | — | $-38.8M |
| Net Margin | — | -1,118,875.0% | — | -1,207,650.0% | — | — | — | -258,973.3% |
| EPS (Basic) | — | $-1.92 | — | $-1.10 | — | — | — | $-2.13 |
| EPS (Diluted) | — | $-1.92 | — | $-1.10 | — | — | — | $-2.13 |
| Shares Outstanding (Basic) | 24.5M | 23.4M | 23.3M | 21.9M | 23.3M | 21.3M | 21.2M | 18.3M |
| Shares Outstanding (Diluted) | 24.5M | 23.4M | 23.3M | 21.9M | 23.3M | 21.3M | 21.2M | 18.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |